Control of Influenza and Pneumococcal Disease in Long-Term Care Facilities (LTCFs) 2016 – 2017

Key Recommendations

Everyone aged 6 months and older should receive flu vaccine every year. This season, the Advisory Committee on Immunization Practices (ACIP) is recommending vaccination with either the inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV). Vaccination should not be delayed to procure a specific vaccine formulation. Begin offering flu vaccine as soon as it is available.

This year there is no preferential recommendation for any one age-appropriate inactivated flu formulation over another. Choice of which influenza vaccine formulation to use should primarily be driven by the age indication, contraindications and precautions. There is no current preference for quadrivalent vs. trivalent or high-dose vs. adjuvanted vs. standard dose.

New! Live attenuated influenza vaccine (LAIV) is not recommended for the 2016-2017 season: The ACIP has made an interim recommendation that quadrivalent live attenuated influenza vaccine (LAIV4) should not be used for the 2016-2017 flu season. Please see page 3 for additional details.

New! Changes to guidelines related to egg allergy: The ACIP now recommends that any licensed influenza vaccine formulation may be administered to persons with egg allergy of any severity. Please see page 4 for more detailed guidance to ensure proper evaluation and safe administration.

New! New formulations:

- Fluad (Seqirus) contains the adjuvant MF59 and is an inactivated trivalent vaccine for persons ≥65 years of age. Adjuvants help create a stronger immune response to vaccines.

- Flucelvax Quadrivalent (Seqirus) is a cell culture-based inactivated quadrivalent influenza vaccine for persons ≥4 years of age. (Last year this vaccine had been trivalent and only approved for those ≥18 years.)

- Afluria quadrivalent inactivated influenza vaccine (Seqiris) was licensed by the FDA in August 2016, for use in persons ≥18 years of age.

Use annual flu vaccination to assess patients for the need for other vaccines, including Tdap and pneumococcal conjugate (PCV13) and pneumococcal polysaccharide (PPSV23) vaccines.
Influenza Prevention and Control Recommendations:

Flu vaccination of health care workers protects the health care workers, their patients and their families. Flu vaccination is an occupational health and patient safety issue.

Influenza Prevention and Control Measures Summary
Strategies for the prevention and control of influenza in long-term care facilities include:

- Annual influenza vaccination of all residents and health-care personnel
- Age-appropriate vaccination of residents with pneumococcal vaccines
- Standard and droplet precautions with suspect or confirmed influenza cases
- Active surveillance and influenza testing for new cases
- Restriction of ill visitors and personnel
- Rapid administration of antiviral medications for treatment and prophylaxis
- Handwashing and respiratory hygiene/cough etiquette programs

2016-2017 Influenza Vaccine Composition
For 2016–17, U.S.-licensed influenza vaccines are different from the 2015–16 vaccines. The composition for 2016-17 represents a change in the influenza A(H3N2) virus, and a switch in lineage for the influenza B viruses.

- Trivalent influenza vaccines contain:
  - an A/California/7/2009 (H1N1)pdm09-like virus
  - an A/Hong Kong/4801/2014 (H3N2)-like virus (New!)
  - a B/Brisbane/60/2008-like (Victoria lineage) virus (this strain was in last year’s quadrivalent vaccine)

- Quadrivalent vaccines contain the above three viruses and a second influenza B strain, B/Phuket/3073/2013-like/(Yamagata lineage) virus (this strain was in last year’s trivalent and quadrivalent vaccines)

Timing of Flu Vaccination:
Vaccination should occur before the onset of influenza activity in the community. To avoid missed opportunities for vaccination, providers should offer flu vaccination at routine health visits and during hospitalizations as soon as vaccine is available, particularly for young children who may need two doses. Although CDC recommends vaccination occur by October if possible, vaccination should continue to be offered in November and throughout the flu season as long as flu viruses are circulating. While seasonal influenza outbreaks can happen as early as October, most of the time influenza activity peaks in January or later. Since it takes about two weeks after vaccination for antibodies to develop in the body that protect against influenza virus infection, it is best that people get vaccinated so they are protected before influenza begins spreading in their community. In New England, flu activity lasts usually through April and May.

Vaccination of Residents and Staff
Use a systematic approach to vaccination, with checklists, to increase immunization levels:

- Vaccinate all staff and residents against influenza every year.

- CDC, the Advisory Committee on Immunization Practices (ACIP), MDPH and the Healthcare Infection Control Practices Advisory Committee (HICPAC) recommend that all U.S. health care workers get vaccinated annually against influenza. Health care workers include (but are not limited to) physicians, nurses, nursing assistants, therapists, technicians, emergency medical service personnel, dental personnel, pharmacists, laboratory personnel, autopsy personnel, students and trainees, contractual staff not employed by the health-care facility, and persons (e.g., clerical, dietary, housekeeping, laundry, security, maintenance, administrative, billing, and volunteers) not
directly involved in patient care but potentially exposed to infectious agents that can be transmitted to and from health care workers and patients.

- **In Massachusetts during 2015-2016, nearly 25% of healthcare workers in LTCFs declined influenza vaccine.** By getting vaccinated, healthcare workers help protect themselves, their families at home, and their patients.

- Vaccinate residents against flu when vaccine is available. Vaccinate residents admitted from September through March on admission.

- Ensure that written policies include annual flu vaccination for residents and staff, and pneumococcal vaccines (PPSV23 and PCV13) and Tdap vaccination for residents.

- Include Vaccine Information Statements (VIS) for PPSV23, PCV13, Tdap and flu vaccines in the admission packet. Vaccine Information Statements (VISs) for all vaccines in many languages: [www.immunize.org/vis](http://www.immunize.org/vis).

- Obtain consent for vaccination from the resident or family member on admission.

- Implement standing orders to administer flu, PCV13, PPSV23 and Tdap vaccines. Remember, doses of PCV13 and PPSV23 should be administered in a series and not on the same day. (If given at the same time, or at shorter than the recommended interval, those doses do not need to be repeated.) Other routine vaccines for adults are safe and effective when administered simultaneously in separate syringes at different anatomical sites.

- Use chart audits to ensure that there is documentation in every chart that the resident has been offered PPSV23, PCV13, and Tdap vaccines and annual influenza vaccine.

- Consider residents with uncertain immunization histories NOT immunized and vaccinate accordingly. The benefits of vaccination far outweigh any concerns about revaccination.

### Vaccination of Family Members and Visitors

Inform family members and other visitors about their role in the transmission of flu to patients and encourage them to get vaccinated. To find flu vaccine, they can call their health care provider or local board of health, visit [https://www.mylocalclinic.com/fcss/](https://www.mylocalclinic.com/fcss/) for a list of flu vaccination clinics by town.

### Live Attenuated Influenza Vaccine Not Recommended for the 2016-2017 Season

The Advisory Committee on Immunization Practices (ACIP) has made an interim recommendation that LAIV4 should not be used for the 2016-2017 flu season. This recommendation was made in light of the poor vaccine effectiveness against influenza A (H1N1) in the U.S. during the 2013-2014 and 2015-2016 seasons.

Possible causes for reduced LAIV effectiveness include: 1) suboptimal performance of the new A/Bolivia(H1N1) vaccine component which had been added this past year to make vaccine more heat stable; 2) potential interference among live viruses in the quadrivalent vaccine; and 3) reduced immunogenicity of LAIV as a result of a more highly vaccinated population in recent years, compared to populations of earlier years. There are no concerns about the safety of LAIV.

How well the flu vaccine works (or its ability to prevent flu illness) can range widely from season to season and can be affected by a number of factors, including characteristics of the person being vaccinated, the similarity between vaccine viruses and circulating viruses, and the vaccine formulations used.

The change in the LAIV recommendation for this flu season is the result of the annual efforts to measure influenza vaccine effectiveness. It is an example of CDC and the ACIP using new data to hone public health policy in order to recommend the most effective vaccines. Researchers, CDC, the FDA and AstraZeneca (manufacturer of FluMist), are all committed to gaining insight into this issue and are continuing to review data as it becomes available. Although not recommended by the ACIP for the 2016-17 season, because LAIV is a licensed product, it is available for purchase.

For more information, see CDC’s press release explaining the decision, and pages 14-17 in the ACIP recommendations. In addition, CDC’s flu website is being updated to reflect these all these recommendations. We have also created an MDPH LAIV resource page.
Changes to guidance related to the management of egg allergic persons:
Anaphylaxis after influenza vaccine is rare, about 1.3 to 1.5 events per million doses, about the same rate as anaphylaxis after other childhood vaccines. As is the case with other vaccines, influenza vaccines contain various different components that may cause allergic reactions. Reviews of studies of experience with the use of IIV, and more recently LAIV, indicate that severe allergic reactions to the currently available egg-based influenza vaccines in persons with egg allergy of any severity are unlikely.

Recommendation
Although history of severe allergic reaction is a labeled contraindication to influenza vaccines, this year the ACIP recommends that any licensed influenza vaccine formulation may be administered to persons with egg allergy of any severity. To ensure safety, providers should follow the guidance outlined below:

a. Persons with a history of egg allergy who have experienced only hives after exposure to egg should receive influenza vaccine. Any licensed and recommended influenza vaccine (i.e., any age-appropriate IIV or RIV) that is otherwise appropriate for the recipient's age and health status may be used.

b. Persons who report having had reactions to egg involving symptoms other than hives, such as angioedema, respiratory distress, lightheadedness, or recurrent emesis; or who required epinephrine or another emergency medical intervention, may similarly receive any licensed and recommended influenza vaccine (i.e., any age-appropriate IIV or RIV) that is otherwise appropriate for the recipient's age and health status. The selected vaccine should be administered in an inpatient or outpatient medical setting (including but not necessarily limited to hospitals, clinics, and physician offices). Vaccine administration should be supervised by a healthcare provider who is able to recognize and manage severe allergic conditions. Clinics and practices will need to determine if they have the trained staff, protocols and equipment in place to safely vaccinate those with severe egg allergy or refer them to their medical home or another provider.

c. A previous severe allergic reaction to influenza vaccine, regardless of vaccine component suspected of being responsible, is a contraindication to future receipt of the vaccine.

d. The ACIP does not express a preference for the use of egg-free flu formulations in egg-allergic patients. However, an egg-free recombinant flu vaccine (RIV3), Flublok, is available for those ≥18 years of age and some providers may choose to administer RIV3 to their severely egg-allergic patients. The cell culture vaccine, Flucelvax, has a much smaller amount of egg protein since the original virus was grown in eggs, but mass production of that vaccine does not occur in eggs. Flucelvax contains an estimated total egg protein that is less than 50 femtograms (5x10^-8µg) total egg protein (and less ovalbumin) per 0.5 mL dose.

Remember, persons who are able to eat lightly cooked egg (e.g., scrambled egg) without reaction are unlikely to be allergic and can receive any licensed influenza vaccine. Egg-allergic persons might tolerate egg in baked products (e.g., bread or cake). Tolerance to egg-containing foods does not exclude the possibility of egg allergy. Egg allergy can be confirmed with a consistent medical history of adverse reactions to eggs and egg-containing foods, plus skin and/or blood testing for immunoglobulin E antibodies to egg proteins.

Observation period after vaccination
In addition, egg allergic individuals no longer need to be observed for 30 minutes post vaccination for signs and symptoms of allergic reactions. According to the Vaccine Safety Datalink (VSD) study of over 25 million doses, anaphylaxis occurred at rate of 1.31 per million. In over 60% of the cases, they occurred at greater than 30 minutes post vaccination. However, providers should continue with the general recommendation to observe all patients for 15 minutes after vaccination to decrease the risk for injury should they experience syncope.

For full guidance on management of those with egg allergy, see pages 26, 29-30 and 33 in the ACIP recommendations.

General Plan for Response to Acute Vaccine Reactions
Although anaphylactic reactions are rare after vaccination, their immediate onset and life-threatening nature require that all personnel and facilities providing vaccinations have procedures in place for anaphylaxis
management. All vaccination providers should be familiar with the office emergency plan and be currently 
certified in cardiopulmonary resuscitation. Epinephrine and equipment for maintaining an airway should be 
available for immediate use.

**Influenza, Neurologic and Neuromuscular Conditions, and Congregate Housing:**
Children and adults with neurological and neuromuscular conditions (including disorders of the brain, spinal 
cord, peripheral nerve, and muscle such as cerebral palsy, epilepsy [seizure disorders], stroke, intellectual 
disability [mental retardation], moderate to severe developmental delay, muscular dystrophy, or spinal cord 
injury) are at increased risk of complications from influenza. These conditions can compromise respiratory 
function, handling of secretions and increase the risk of aspiration. Like everyone else six months of age and 
older, they should receive influenza vaccine every year. A [CDC study](https://www.cdc.gov) found that in 2011-2012, only about 
half of children and young adults with in this high risk group received influenza vaccine.

People with neurological and neuromuscular conditions who live in congregate housing (e.g., group homes) 
and/or attend day programs may be exposed to influenza throughout the season. **They should receive flu 
vaccine as soon as it is available.** Staff at these facilities should be vaccinated as well. In addition, 
when outbreaks of influenza-like illness (fever with cough and/or sore throat) occur in a group home 
or day program serving vulnerable populations, healthcare providers should be immediately notified 
and should consider rapid antiviral treatment of ill individuals as well as antiviral prophylaxis of 
individuals who were exposed.

Outbreaks across the age spectrum in these settings have occurred annually in Massachusetts and have 
resulted in serious illness and even death. So, MDPH recommends proactive development of an influenza 
outbreak response protocol within agencies serving vulnerable populations, to facilitate a rapid response 
when an outbreak occurs, as well as immediate notification of MDPH and other appropriate agencies.

**Influenza Surveillance:**
Throughout the year, and especially during flu season, conduct surveillance for respiratory illness with fever 
and use influenza testing to identify outbreaks so infection control measures can be promptly initiated in all 
settings, including inpatient and outpatient settings.

**Influenza Reporting:**
All positive laboratory findings indicative of influenza virus infection are reportable directly to MDPH, in 
accordance with 105 CMR 300.000 (Reportable Diseases, Surveillance and Isolation and Quarantine 
Requirements).

1) Immediately report the following influenza-related cases by phone to the Division of Epidemiology 
and Immunization at 617-983-6800 and to your local board of health. Providers in the city of Boston 
should report these cases directly to the Boston Public Health Commission at 617-534- 5611. This applies to 
all strains of influenza:

- **Suspected and confirmed deaths related to influenza in children under 18 and in pregnant women**
- **Unusual or unusually severe cases of influenza or influenza-like illness (ILI), e.g., with encephalopathy, 
myocarditis, or pericarditis. ILI is defined as fever with cough and/or sore throat.**
- **Case(s) or clusters of ILI in long-term care facilities, group homes, shelters, prisons or other high risk 
settings**
- **Unusual clusters of ILI in daycare and elementary schools**
- **Cases of suspected or proven antiviral treatment or prophylaxis failure**
- **Suspect novel or variant influenza, e.g., travel-associated, animal-associated, avian influenza A H5N1 or 
H7N9, influenza A H3N2v, other highly pathologic avian influenza**
- **ILI in employees of swine or poultry farms**

**Clusters in hospitals and long-term care:** Report clusters of influenza-like illness to MDPH via faxed 
teleform. Teleforms are available by calling 617-983-6801, and at 
Please provide as much detail on these forms as possible. Upon receipt of the teleform, an epidemiologist...
Influenza testing and infection control (including antiviral treatment), below: Providers should routinely check for updates at www.mass.gov/flu and www.cdc.gov/flu/professionals/.

Infection Control: To prevent the transmission of all respiratory infections, including influenza, in health care settings, implement the following infection control measures at the first point of contact with a potentially infected person. These should be incorporated into infection control practices as one component of standard precautions. Tools to help promote and implement these recommendations are available at www.cdc.gov/flu/professionals/infectioncontrol.

1) Assess the influenza and pneumococcal vaccination status of all patients and the flu vaccination status of all staff. Vaccinate all susceptible patients and staff.


3) Active surveillance and testing for new illness and cases: Educate staff about the signs and symptoms of influenza-like illness.

4) Respiratory hygiene/cough etiquette: Post visual alerts (in appropriate languages) at the entrance to outpatient facilities (e.g., emergency departments, physician offices, outpatient clinics) instructing patients and persons who accompany them (e.g., family, friends) to inform health care personnel of symptoms of a respiratory infection when they first register for care and to practice respiratory hygiene/cough etiquette. Posters, brochures and fact sheets promoting cough etiquette and handwashing in multiple languages are available from the Massachusetts Health Promotion Clearinghouse at https://massclearinghouse.ehs.state.ma.us/.

5) Novel strains of influenza: If you suspect any novel strain of influenza, please contact your local board of health and MDPH immediately at 617-983-6800. Highly-pathogenic avian influenza (HPAI) A H5 viruses were identified in birds in the United States in December 2014 and the first half of 2015. The majority of these infections occurred in poultry, including backyard and commercial flocks. These HPAI A H5 viruses are not known to have caused disease in humans. There have been no cases identified in Massachusetts birds to date; Providers should check for updates at http://www.cdc.gov/flu/avianflu/index.htm and at http://www.cdc.gov/flu/swineflu/prevention-strategies.htm.

6) Antiviral drugs are an adjunct to, not a substitute for, vaccination for preventing and controlling influenza. The neuraminidase inhibitors oseltamivir (Tamiflu®), zanamivir (Relenza®), and peramivir (Rapivab®) are currently recommended for use against circulating influenza viruses. The adamantanes (amantadine and rimantadine) are not recommended because of high levels of resistance to these drugs among recently circulating influenza A (H3) and 2009 H1N1 influenza viruses.

Prompt empiric antiviral treatment: Clinical judgment is an important factor in treatment decisions for patients presenting with influenza-like illness. Prompt empiric antiviral treatment with influenza antiviral medications is recommended while results of definitive diagnostic tests are pending, or if diagnostic testing is not possible, for patients with clinically suspected influenza illness who have:

• Illness requiring hospitalization,
• Progressive, severe, or complicated illness, regardless of previous health status, and/or
• Increased risk for severe disease. Antiviral treatment, when clinically indicated, should not be delayed pending definitive laboratory confirmation of influenza. Influenza antiviral medications are most effective when initiated within the first 2 days of illness, but these medications may also provide benefits for severely ill patients when initiated even after 2 days. Guidance on use of antivirals may change depending upon resistance data. Consult CDC’s latest recommendations on antiviral use at www.cdc.gov/flu/professionals/antivirals/.

**Antiviral agents for outbreak control:** Used in conjunction with vaccination and behavioral measures, including droplet precautions and cohorting of ill residents, antiviral agents are a key component of outbreak control in long-term care facilities and other institutional settings. Antiviral chemoprophylaxis should be considered following identification of any laboratory-confirmed case of influenza or in the presence of more than one resident meeting criteria for influenza-like illness (fever with cough and/or sore throat) in a facility or area of the facility.

- When antiviral agents are used for outbreak control, they should be administered to all residents regardless of immunization status.
- All unvaccinated staff should be re-offered influenza vaccine. They should also be offered chemoprophylaxis if they care for persons at high risk for complications.
- All staff, regardless of vaccination status, should be offered chemoprophylaxis if there are any indications that the outbreak is caused by a variant strain of influenza that is not covered by the vaccine.
- The drugs should be continued for a minimum of 2 weeks and as long as 10 days after the last onset of symptoms.
- The antiviral dose for each resident is determined based on age, renal function, liver function and other pertinent characteristics.
- Pre-approved medication orders, or plans to obtain physician’s orders on short notice, should be in place to ensure that chemoprophylaxis can be started as soon as possible.
- Additional CDC guidance concerning control of influenza in LTCFs is available at http://www.cdc.gov/flu/professionals/infectioncontrol/ltc-facility-guidance.htm

Clinicians should be alert to changes in antiviral recommendations that might occur as additional antiviral resistance data becomes available during the 2016-2017 season. For more information go to http://www.cdc.gov/flu/professionals/antivirals/antiviral-infection-control.htm

7) **Rapid testing reminder:** Point of care rapid tests capable of detecting influenza A and B virus infections are available, but health care providers and public health personnel should be aware that rapid influenza diagnostic tests have limited sensitivity and false negative results are common. Thus, negative results from rapid influenza diagnostic test should not be used to guide decisions regarding treating patients with influenza antiviral medications. In addition, false positive tests can occur and are more likely when influenza is rare in the community. When laboratory confirmation is desired, use RT-PCR and/or viral culture.

**Influenza Testing:** Diagnostic testing for influenza can aid clinical judgment and guide treatment decisions and control measures. Clinical testing services performed on specimens submitted to a state public health laboratory provide important diagnostic information to the clinician and also contribute to public health respiratory surveillance response and control measures. As a specific example, an influenza B strain submitted to the Massachusetts State Public Health Laboratory (MA SPHL) in March 2012 was the first identified isolate that later began to circulate widely and was then incorporated into the 2013-14 and 2014-15 influenza vaccines. Specific testing services provided by the MA SPHL may assist the clinician as follows:

- **Define the start of the influenza season:** Rapid antigen testing for detecting influenza A and B virus infections is widely available. Rapid influenza diagnostic tests vary in performance characteristics. False
negative and false positive results can occur when flu prevalence is low in the community. For this reason, MA SPHL requests that clinical laboratories consider submitting their first influenza rapid positive original samples of the season (beginning in October) to MA SPHL for confirmation. For more information: www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm.

- **Diagnose influenza or other respiratory infections:** Diagnostic tests for influenza performed at the MA SPHL include a “respiratory panel” to identify seasonal and novel influenza types/subtypes followed by testing of influenza negative samples for the presence of adenovirus, respiratory syncytial virus (A/B), parainfluenza virus (1-4), coronavirus (HKU1, OC43, NL63, 229E), human metapneumovirus and rhinovirus/enterovirus using polymerase chain reaction (PCR). There is no charge for these tests. The turnaround time for results is usually a few days, but varies depending on the test performed. Results are returned electronically or by fax and mail to the submitting provider.

- **Monitor trends in influenza antiviral resistance:** MA SPHL performs surveillance testing for influenza antiviral resistance and provides this information in its weekly influenza report. Diagnostic antiviral resistance testing is currently coordinated with CDC and is offered on a case-by-case basis. Providers are encouraged to submit samples from influenza cases with suspect antiviral drug resistance.

- **Rapid identification of new or novel influenza or other viral infections:** MA SPHL is able to rapidly determine the presence of a novel or variant influenza strain using the CDC diagnostic panel. Rapid antigen testing and commercially-available RT-PCR tests may not detect novel or variant strains of influenza and most are unable to differentiate between seasonal, novel or variant influenza strains. Therefore, respiratory specimens should be collected from any patient suspected of having atypical or novel infections with H3N2v or avian influenza H7N9, for example. These suspicions may be based on travel history or animal exposure.

**Specimen Collection and Shipping to MA SPHL:**

Flu specimens should be collected as soon as possible after onset of illness, preferably within three days (72 hours). Specimens collected after 72 hours are usually unsuitable for testing. Specimens should be submitted immediately after collection to MA SPHL in order to be tested within three days of collection. If samples will be shipped to MA SPHL >3 days from collection or on a Friday but are collected within 72 hrs, they should be frozen at <-20ºC and shipped with ice packs on Monday. This variation must be noted on the specimen submission form to avoid an “unsatisfactory for testing” designation.

- For information on influenza specimen collection and transportation, or to speak with an immunization epidemiologist, call MDPH at 617-983-6800.

- Information of specimen collection and submission, including the respiratory surveillance specimen submission form may be found at: www.mass.gov/eohhs/docs/dph/laboratory-sciences/flu-virus-collection.pdf and www.mass.gov/eohhs/docs/dph/laboratory-sciences/flu-specimen-submission-form.pdf.

**Pneumococcal Vaccine Recommendations:**

Since 2014, the ACIP recommends that PCV13 and PPSV23 should be administered routinely in a series to all immunocompetent adults aged ≥65 years. **PCV13** should be administered only once for all adults. **The recommended intervals between PCV13 and PPSV23 vaccines** were updated last year and published in the MMWR. Specific recommendations are based on a person’s previous pneumococcal vaccine history.

- **Persons who are pneumococcal vaccine-naïve.** Adults aged ≥65 years who have not previously received pneumococcal vaccine or whose previous vaccination history is unknown should receive a single dose of PCV13 first, followed by a dose of PPSV23. The dose of PPSV23 should be given ≥1 year after a dose of PCV13. If PPSV23 cannot be given during this time window, the dose of PPSV23 should be given during the next visit.

- **Persons previously vaccinated with PPSV23.** Adults aged ≥65 years who have previously received ≥1 doses of PPSV23 also should receive a single dose of PCV13 if they have not yet received it. A dose
of PCV13 should be given ≥1 year after receipt of the most recent PPSV23 dose. For those for whom an additional dose of PPSV23 is indicated, this subsequent PPSV23 dose should be given ≥1 year after PCV13 and ≥5 years after the most recent dose of PPSV23.

- The two vaccines should not be co-administered. However, if doses of PPSV23 and PCV13 are inadvertently given on the same day or earlier than the recommended interval, those doses do not need to be repeated.

- Adults 19 years and older at increased risk for pneumococcal disease who have already received a dose of PCV13 at 64 years or younger should not receive another dose of PCV13 at 65 years or older.

- For adults ≥65 years with immunocompromising conditions, functional or anatomic asplenia, CSF fluid leaks or cochlear implants, the recommended interval between a dose of PCV13 and PPSV23 remains ≥8 weeks. This interval minimizes the risk window for invasive pneumococcal disease caused by serotypes unique to PPSV23 in these highly vulnerable groups.

For more details about the sequential schedule and intervals, please see the algorithm below.

**Sequential Administration and Recommended Intervals for PCV13 and PPSV23 for Immunocompetent Adults Aged ≥65 Years**

1. **Pneumococcal vaccine-naïve persons aged ≥65 years:**
   - PCV13 at age ≥65 years
   - PPSV23 after ≥1 year

2. **Persons who previously received PPSV23 at age ≥65 years:**
   - PPSV23 already received at age ≥65 years
   - PCV13 after ≥1 year

3. **Persons who previously received PPSV23 before age 65 years who are now aged ≥65 years:**
   - PPSV23 already received at age <65 years
   - PCV13 at age ≥65 years after ≥1 year
   - PPSV23 after ≥5 years

(Footnotes continue on the next page.)

1. If doses of PPSV23 and PCV13 are inadvertently given on the same day or earlier than the recommended interval, those doses do not need to be repeated.

2. For adults in this age group with immunocompromising conditions, functional or anatomic asplenia, CSF fluid leaks or cochlear implants, the recommended interval is ≥8 weeks.

3. For those who previously received PPSV23 when aged <65 years and for whom an additional dose of PPSV23 is indicated when aged ≥65 years, this subsequent PPSV23 dose should be given ≥1 year after PCV13 and ≥5 years after the most recent dose of PPSV23.

Great resource: The above figure only outlines pneumococcal vaccine recommendations for those ≥65 years of age. The CDC job aid [Pneumococcal Vaccine Timing for Adults](https://www.cdc.gov/vaccines/acip/acip-reports/pneumovax-vaccine-timing-adults.html) contains a number of algorithms.
and a summary table. It was developed to help providers understand the complex pneumococcal recommendation across both age and risk groups -- and is an outstanding resource.

The recommendations for routine PCV13 use among adults aged ≥65 years will be reevaluated and revised as needed. CDC’s Pneumococcal Frequently Asked Questions was developed to help healthcare professionals address common questions patients ask regarding pneumococcal vaccination. Information and other resources can be found on CDC’s Pneumococcal Disease and Pneumococcal Vaccination web pages.

**Insurance Coverage and Pneumococcal Vaccines**

Most private health insurance covers pneumococcal vaccines. Check with the insurance provider for details on whether there is any cost to your patient and for a list of in-network vaccine providers. Medicare Part B covers the cost of two recommended doses of pneumococcal vaccine when administered 1 year apart. (i.e., 11 full months have passed following the month in which the previous pneumococcal vaccine was administered). As with other preventive care and vaccines, Medicare beneficiaries may not need to pay for the immunization if the doctor or other qualified health care provider accepts assignment (Medicare payment) for giving the vaccine. However, patients should check with their provider and plan to review the details of their coverage. Guidance for providers about Medicare Part B billing for pneumococcal vaccines can be found at: [http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/MM9051.pdf](http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/MM9051.pdf)

CMS does have a free subscription service, which allows subscribers to receive notification by e-mail when new information is available. Subscribers select from a list of topics. **Please note that there is not a specific category regarding immunizations.** It can be found at: [http://www.cms.gov/About-CMS/Agency-Information/Aboutwebsite/EmailUpdates.html](http://www.cms.gov/About-CMS/Agency-Information/Aboutwebsite/EmailUpdates.html). For questions, call the Medicare Call Center at 1-800-MEDICARE (1-800-633-4227).

**Regulations, Requirements and Reimbursement**

Massachusetts Regulation requires LTC facilities to offer flu vaccine to all personnel. Influenza is often introduced into and spread throughout a facility by staff or visitors. Flu vaccine may be less effective in the very elderly and some vaccinated LTC residents may remain susceptible. It is important to reduce their exposure to flu. Healthcare provider vaccination reduces mortality in elderly patients.

Regulation [105 CMR 150.002(D)[8]] requires LTC facilities to provide information about the risks and benefits of flu vaccine and flu vaccine at no cost to all personnel. All LTC facilities are also required to report information to MDPH documenting compliance with the vaccination requirement, in accordance with the reporting and data collection guidelines of the Commissioner (105 CMR). MDPH Circular Letter DHCQ 15-12-650 is available at the following: [http://www.mass.gov/eohhs/docs/dph/quality/hcq-circular-letters/2015/dhcq-650.pdf](http://www.mass.gov/eohhs/docs/dph/quality/hcq-circular-letters/2015/dhcq-650.pdf). For questions regarding the reporting requirements, please contact Eileen McHale at the Bureau of Healthcare Safety and Quality at 617-753-7324 or eileen.mchale@state.ma.us.


**Medicare reimbursement for influenza and pneumococcal vaccination:**

At this time, Medicare B reimbursement rates for the cost of administration of influenza and pneumococcal vaccine in our state are not available. For more information on Medicare Part B reimbursement for vaccines, see:

If you have questions regarding pricing and reimbursement under Medicare Part B, including pneumococcal vaccines, please call the Medicare Call Center at 1-800-MEDICARE (1-800-633-4227).

**Tdap Vaccine**

During 2001 through 2008, 49% of tetanus cases in the U.S. were among persons 50 years of age or older. The risk of dying from tetanus was five times greater in patients >65 years. Across the nation, including in Massachusetts, there has been an increase in the number of cases of pertussis (whooping cough). **Adults aged 19 years and older, including those older than 65, who have not yet received a dose of Tdap should receive a single dose.** Currently, Tdap is recommended only for a single dose across all age groups, except in pregnant women, who should get a dose during every pregnancy.

When feasible, Boostrix should be used for adults aged 65 years and older; however, ACIP concluded that either vaccine (Boostrix or Adacel) administered to a person 65 years or older is immunogenic and would provide protection. Providers should not miss an opportunity to vaccinate persons aged 65 years and older with Tdap. Therefore, providers may administer the Tdap vaccine they have available. A dose of either vaccine may be considered valid. Tdap can be administered **regardless** of interval since the last tetanus- or diphtheria-toxoid containing vaccine. After receipt of Tdap, persons should continue to receive Td for routine booster immunization every 10 years.

**Vaccine Ordering and Locating Clinics:**

**Providers Wishing to Order Flu Vaccine for Private Purchase:**
The national **Influenza Vaccine Availability Tracking System** (IVATS) assists providers wishing to privately purchase flu vaccine. IVATS identifies available doses of influenza vaccine by formulation and distributor/vendor throughout the season.

**Location of Flu and Adult Vaccination Services:**
Flu vaccination clinics are listed on the mylocalclinic.com website sponsored by the Massachusetts Health Officers Association (MHOA). MDPH urges agencies to post their clinics on this website. Many boards of health (BOHs) may have clinics that make flu and other vaccines available to both adults and children. BOHs can be contacted individually for questions about possible flu vaccination clinics in Massachusetts municipalities, including the age groups served.

**HealthMap Vaccine Finder** assists the public with locating influenza and adult vaccination services within their communities. It is a free, online service where users can search for locations that offer immunizations. Its staff works with partners such as clinics, pharmacies, and health departments to provide accurate and up-to-date information about vaccination services. MDPH urges providers and other agencies to **register their locations** on the HealthMap Vaccine Finder site too.

**Guidance and Resources for Large Scale Immunization Clinics:**

- **Guidelines for Large-Scale Influenza Vaccination Clinic Planning.** This webpage provides guidelines and recommendations to assist with planning influenza vaccination clinics. Topics include clinic logistics as well as vaccine storage, handling, and administration.
- **Checklist of Best Practices for Vaccination Clinics Held at Satellite, Temporary, or Off Site Locations.** Outlines CDC’s Best Practices that are essential for patient safety and vaccine effectiveness in these settings.
- **CDC At-A-Glance Resource Guide - Vaccine Administration and Storage and Handling.** This is a quick guide to key web resources on immunization, vaccine administration, and vaccine storage and
handling. The guide includes CDC guidelines, an immunization checklist, educational webinars, and standing orders.

- **MDPH Influenza Vaccine Guidelines and Tools.** This webpage contains information about influenza vaccine and links to guidance about planning flu and other mass immunization campaigns, standing orders, screening forms, consent forms, and MDPH-specific vaccine management guidance.

- **One & Only Campaign.** The One & Only Campaign is a public health campaign, led by the Centers for Disease Control and Prevention (CDC) and the Safe Injection Practices Coalition (SIPC), to raise awareness among patients and healthcare providers about safe injection practices.
  - [Frequently Asked Questions](#) Regarding Safe Practices for Medical Injections
  - [Pocket Card](#) on Injection Safety Guidelines from CDC

**References and Resources:**

For questions about influenza, please call the Massachusetts Department of Public Health Immunization Program at 617-983-6800 or your local board of health. For questions about state-supplied influenza vaccine, please call the Vaccine Unit at 617-983-6828.

- [CDC Influenza Toolkit for Long-Term Care Employers](http://www.cdc.gov/flu/toolkit/long-term-care/) (resources for increasing vaccination rates among healthcare personnel in LTCFs):

- [CDC. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2016-17 Season](http://www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6505.pdf)

- [CDC. Intervals between PCV13 and PPSV23 Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP)](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6434a4.htm?s_cid=mm6434a4_e)

- [CDC. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP).](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6337a4.htm?s_cid=mm6337a4_w) MMWR, 2014, 63;822-825.

- [CDC. Interim Guidance for Infection Control Within Healthcare Settings When Caring for Patients with Confirmed, Probable, or Cases Under Investigation of Novel Influenza A Associated with Severe Disease, January 2014.](http://www.cdc.gov/flu/avianflu/h7n9-infection-control.htm)


- [CDC. Injection Safety and Vaccine Administration Errors at an Employee Influenza Vaccination Clinic, New Jersey, 2015.](https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6449a3.htm) MMWR 2016;1363-1364.


CDC. Influenza Vaccination of Health-Care Personnel: Recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP) 2006:55(No. RR-2). [www.cdc.gov/mmwr/preview/mmwrhtml/rr5502a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5502a1.htm).

Vaccine Information Statements (VISs) for all vaccines in many languages: [www.immunize.org/vis](http://www.immunize.org/vis).

Standing orders for IIV, pneumococcal vaccine, Tdap and other vaccines are available at [www.immunize.org](http://www.immunize.org) or [www.mass.gov/dph/imm](http://www.mass.gov/dph/imm)